Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

Trial Profile

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Etanercept (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Psoriasis
  • Focus Therapeutic Use
  • Acronyms MMAPPS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Mar 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 May 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top